|
ATP6AP2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.63791202822949E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.03028696685215E-13 |
| Normal-vs-Stage2 |
3.61669999999759E-05 |
| Normal-vs-Stage3 |
1.80970016749882E-10 |
| Normal-vs-Stage4 |
1.62525548574877E-12 |
| Stage1-vs-Stage2 |
2.220800E-01 |
| Stage1-vs-Stage3 |
4.122200E-01 |
| Stage1-vs-Stage4 |
1.032870E-04 |
| Stage2-vs-Stage3 |
1.389390E-01 |
| Stage2-vs-Stage4 |
1.123370E-03 |
| Stage3-vs-Stage4 |
1.760290E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.56381590904675E-14 |
| Normal-vs-AfricanAmerican |
5.98239999999306E-05 |
| Normal-vs-Asian |
2.08170003457298E-09 |
| Caucasian-vs-AfricanAmerican |
8.245000E-01 |
| Caucasian-vs-Asian |
5.705200E-01 |
| AfricanAmerican-vs-Asian |
9.410400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.79345468768133E-13 |
| Normal-vs-Female |
1.9533263895255E-12 |
| Male-vs-Female |
4.912200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.16604512104368E-12 |
| Normal-vs-Age(41-60Yrs) |
5.98632254877884E-13 |
| Normal-vs-Age(61-80Yrs) |
7.35719996036721E-09 |
| Normal-vs-Age(81-100Yrs) |
5.223600E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.738400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.098000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.201400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.727400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.796800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.085000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.764100E-04 |
| Classical-VS-Follicular |
3.689600E-01 |
| Classical-VS-Other |
7.262400E-01 |
| Classical-VS-Normal |
1.64324109874769E-12 |
| Tall-VS-Follicular |
1.562850E-03 |
| Tall-VS-Other |
5.241000E-01 |
| Tall-VS-Normal |
6.48370246381091E-14 |
| Follicular-VS-Other |
5.999800E-01 |
| Follicular-VS-Normal |
2.54389999998494E-06 |
| Other-VS-Normal |
3.022500E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.78300049671998E-10 |
| Normal-vs-N1 |
1.37556632751057E-13 |
| N0-vs-N1 |
1.269520E-02 |
|
|
